In it's current formulation, i don't believe it looks promising as a treatment for full blown sepsis/bacteraemia, and I get that impression from this presentation also.
Looking great as a UTI/pre-sepsis treatment, which is still a massive market. And possibly some sort of formulation change such as protein binding could improve the plasma concentration profile.
Still hugely undervalued, but wish management would be more up front.
Ann: Investor Presentation - Spark Plus Healthcare Day, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.005(1.69%) |
Mkt cap ! $86.51M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 30.0¢ | 29.0¢ | $37.22K | 127.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8471 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 17050 | 2 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |